Statin use is associated with a significant reduction in cholesterol content of erythrocyte membranes. A novel pleiotropic effect?

Cardiovascular Drugs and Therapy

Volumn 23, Issue 6, 2009, Pages 471-480

  Tziakas, Dimitrios N ^a   Chalikias, Georgios K ^a   Stakos, Dimitrios ^a   Tentes, Ioannis K ^a   Thomaidi, Adina ^a   Chatzikyriakou, Sofia ^a   Mitrousi, Konstantina ^a   Kortsaris, Alexandros X ^a   Kaski, Juan Carlos ^b   Boudoulas, Harisios ^c   Konstantinides, Stavros ^a  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^b ST GEORGE S HOSPITAL   (United Kingdom)

^c BIOMEDICAL RESEARCH FOUNDATION   (Greece)

Author keywords

Cholesterol content; Coronary artery disease; Erythrocyte membranes; Statins

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CLOPIDOGREL; EZETIMIBE; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NITRATE; OMEGA 3 FATTY ACID; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; CHOLESTEROL;

ACUTE CORONARY SYNDROME; ADULT; ANALYSIS OF VARIANCE; ANGINA PECTORIS; ANGIOCARDIOGRAPHY; ARTICLE; CELL MEMBRANE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG USE; ELECTROCARDIOGRAPHY; ERYTHROCYTE MEMBRANE; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; HUMAN CELL; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; STABLE ANGINA PECTORIS; BLOOD; CLINICAL TRIAL; DRUG EFFECT; MIDDLE AGED;

ACUTE CORONARY SYNDROME; CHOLESTEROL; CORONARY ANGIOGRAPHY; ERYTHROCYTE MEMBRANE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED;

EID: 77649206260     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10557-009-6202-7     Document Type: Article

References (55)

1. Herrmann J, Lerman A. Atherosclerosis in the back yard. J Am Coll Cardiol. 2007;49:2102-2104
2. Kolodgie FD, Burke AP, Nakazawa G, Cheng Q, Xu X, Virmani R. Free cholesterol in atherosclerotic plaques: where does it come from? Curr Opin Lipidol. 2007;18:500-507
3. Moreno PR, Purushothaman KR, Sirol M, Levy AP, Fuster V. Neovascularization in human atherosclerosis. Circulation. 2006;113:2245-2252
4. Virmani R, Kolodgie FD, Burke AP, Finn AV, Gold HK, Tulenko TN, et al. Atherosclerotic plaque progression and vulnerability to rupture. Angiogenesis as a source for intraplaque hemorrhage. Atheroscler Thromb Vasc Biol. 2005;25:2054-2061
5. Arbustini E, Morbini P, D'Armini AM, Repetto A, Minzioni G, Piovella F, et al. Plaque composition in plexogenic and thromboembolic pulmonary hypertension: the critical role of thrombotic material in pultaceous core formation. Heart. 2002;88:177-182
6. Kolodgie FD, Gold HK, Burke AP, Fowler DR, Kruth HS, Weber DK, et al. Intraplaque haemorrhage and progression of coronary atheroma. N Engl J Med. 2003;349:2316-2325
7. Yeagle PL. Cholesterol and the cell membrane. Biochim Biophys Acta. 1985;822:267-287
8. Tziakas D, Kaski JC, Chalikias GK, Romero C, Fredericks S, Tentes IK, et al. Total cholesterol content of erythrocyte membranes is increased in patients with acute coronary syndrome. J Am Coll Cardiol. 2007;49:2081-2089
9. Martinez M, Vaya A, Marti R, Gil L, Lluch I, Carmena R, et al. Erythrocyte membrane cholesterol/phospolipid changes and haemorrheological modifications in familial hypercholesterolemia treated with lovastatin. Thromb Res. 1996;83:375-388
10. Koter M, Brochel M, Chojnowska-Jezierska J, Klikczynska K, Franiak I. The effect of atorvastatin on erythrocyte membranes and serum lipids in patients with type-2 hypercholesterolemia. Eur J Clin Pharmacol. 2002;58:501-506
11. Koter M, Franiak I, Bronchel M, Chojnowska-Jezierska J. Effects of simvastatin and pravastatin on peroxidation of erythrocyte plasma lipids in patients with type-2 hypercholesterolemia. Can J Physiol Pharmacol. 2003;81:485-492
12. Arbustini E. Total erythrocyte membrane cholesterol. An innocent new marker or an active player in acute coronary syndromes ? J Am Coll Cardiol. 2007;49:2090-2092
13. Fox K, Garcia MA, Ardissino D, Buszman P, Camici PG, Crea F, et al. Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J. 2006;27:1341-1381
14. Van de Werf F, Ardissino D, Betriu A, Cokkinos DV, Falk E, Fox KA, et al. Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Management of acute myocardial infarction in patients presenting with STsegment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J. 2003;24:28-66.
15. Bassand JP, Hamm CW, Ardissino D, Boersma E, Budaj A, Fernández-Avilés F, et al. Task Force for Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of European Society of Cardiology. Eur Heart J. 2007;28:1598-1660
16. Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E, et al. STELLAR Study Group. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol. 2003;92:152-160
17. Thygesen K, Alpert JS, White HD. Universal definition of myocardial infarction: Kristian Thygesen, Joseph S. Alpert and Harvey D. White on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Eur Heart J. 2007;28:2525-2538 (Pubitemid 47616190)
18. Braunwald E. Unstable angina: a classification. Circulation. 1989;80:410-414
19. Grundy SM, Cleeman JI, Merz NB, Brewer B Jr, Clark LT, Hunninghake DB, et al. for the Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation. 2004;110:227-239
20. Scanlon PJ, Faxon DP, Audet AM, Scanlon PJ, Faxon DP, Audet AM, et al. ACC/AHA guidelines for coronary angiography. A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on Coronary Angiography). Developed in collaboration with the Society for Cardiac Angiography and Interventions. J Am Coll Cardiol. 1999;33:1756-1824
21. Kaski JC, Chester MR, Chen L, Katritsis D. Rapid angiographic progression of coronary artery disease in patients with angina pectoris. The role of complex stenosis morphology. Circulation. 1995;92:2058-2065
22. Cazzola R, Rondanelli M, Russo-Volpe S, Ferrari E, Cestaro B. Decreased membrane fluidity and altered susceptibility to peroxidation and lipid composition in overweight and obese female erythrocytes. J Lipid Res. 2004;45:1846-1851
23. Miwa S, Inouye M, Ohmura C, Mitsuhashi N, Onuma T, Kawamori R. Relationship between carotid atherosclerosis and erythrocyte membrane cholesterol oxidation products in type 2 diabetic patients. Diabetes Res Clin Pract. 2003;61:81-88
24. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein uitilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248-254
25. Allain CC, Poon LS, Chan CSG, Richmond W, Fu PC. Enzymatic Determination of Total Serum Cholesterol. Clin Chem. 1974;20:470-475
26. Ray KK, Cannon CP. The potential relevance of the multiple lipidindependent (pleiotropic) effects of statins in the management of acute coronary syndromes. J Am Coll Cardiol. 2005;46:1425-1433
27. Calabro P, Yeh ET. The pleiotropic effects of statins. Curr Opin Cardiol. 2005;20:541-546
28. Dietzen DJ, Page KL, Tetzloff TA, Bohrer A, Turk J. Inhibition of 3-hydroxy-3methylglutaryl coenzyme A (HMG CoA) reductase blunts factor VIIa/Tissue Factor and prothrombinase acitivities via effects on membrane phosphatidylserine. Arterioscler Thromb Vasc Biol. 2007;27:690-696
29. Lin H-L, Xu X-S, Lu H-X, Zhang L, Li C-J, Tang M-X, et al. Pathological mechanisms and dose dependency of erythrocyteinduced vulnerability of atherosclerotic plaques. J Mol Cell Cardiol. 2007;43:272-280
30. Caliskan S, Caliskan M, Kuralay F, Onvural B. Effect of simvastatin therapy on blood and tissue ATP levels and erythrocyte membrane lipid composition. Res Exp Med. 2000;199:189-194
31. Uyuklu M, Meiselman HJ, Baskurt OK. Effect of decreased plasma cholesterol by atorvastatin treatment on erythrocyte mechanical properties. Clin Hemorheol Microcirc. 2007;36:25-33.
32. Levy Y, Leibowitz R, Aviram M, Brook JG, Cogan U. Reduction of plasma cholesterol by lovastatin normalizes erythrocyte membrane fluidity in patients with severe hypercholesterolemia. Br J Clin Pharmacol. 1992;34:427-430
33. Lijnen P, Celis H, Fagard R, Staessen J, Amery A. Influence of cholesterol lowering on plasma membrane lipids and cationic transport systems. J Hypertens. 1994;12:59-64. (Pubitemid 24044009)
34. Pogue DH, Moravec CS, Roppelt C, Disch CH, Cressman MD, Bond M. Effect of lovastatin on cholesterol content of cardiac and red blood cell membranes in normal and cardiomyopathic hamsters. J Pharmacol Exp Ther. 1995;273:863-869
35. Dwight JF, Mendes Ribeiro AC, Hendry BM. Effects of HMGCoA reductase inhibition on erythrocyte membrane cholesterol and acyl chain composition. Clin Chim Acta. 1996;256:53-63.
36. Miossec P, Zkhiri F, Paries J, David-Dufilho M, Devynck MA, Valensi PE. Effect of pravastatin on erythrocyte rheological and biochemical properties in poorly controlled type-2 diabetic patients. Diabet Med. 1999;16:424-430
37. Rabini RA, Polenta M, Staffolani R, Tocchini M, Signore R, Testa I, et al. Effect of hydroxymethylglutaryl-CoA reductase inhibitors on the functional properties of erythrocyte membranes. Exp Mol Pathol. 1993;59:51-57
38. Lijnen P, Fagard R, Staessen J, Thijs L, Amery A. Erythrocyte membrane lipids and cationic transport systems in men. J Hypertens. 1992;10:1205-1211
39. Schick BP, Schick PK. Cholesterol exchange in platelets, erythrocytes, and megakaryocytes. Biochim Biophys Acta. 1985;833:281-290
40. Chabanel A, Flamm M, Sung KL, Lee MM, Schachter SL, Chien S. Influence of cholesterol content on red cell membrane viscoelasticity and fluidity. Biophys J. 1983;44:171-176
41. Kanakaraj P, Singh M. Influence of hypercholesterolemia on morphological and rheological characteristics of erythrocytes. Atherosclerosis. 1989;76:209-218 (Pubitemid 19101041)
42. London IM, Schwarz H. Erythrocyte metabolism. The metabolic behavior of the cholesterol of human erythrocytes. J Clin Invest. 1992;32:1248-1252
43. Gold JC, Phillips MC. Effects of membrane lipid composition on the kinetics of cholesterol exchange between lipoproteins and different species of red blood cells. Biochim Biophys Acta. 1990;1027:85-92.
44. Rothblat GH, Arbogast LY, Ray EK. Stimulation of esterified cholesterol accumulation in tissue culture cells exposed to high density lipoproteins enriched in free cholesterol. J Lipid Res. 1978;19:350-358
45. d'Hollander F, Chavallier F. Movement of cholesterol in vitro in rat blood and quantitation of the exchange of free cholesterol between plasma and erythrocytes. J Lipid Res. 1972;13:733-744
46. Gottlieb MH. Rates of cholesterol exchange between human erythrocytes and plasma lipoproteins. Biochim Biophys Acta. 1980;600:530-541
47. Quarfordt SH, Hilderman HL. Quantitation of the in vitro free cholesterol exchange of human red cells and lipoproteins. J Lipid Res. 1970;11:528-535
48. Kuypers FA, Roelofsen B, Op Den Kamp JAF, Van Deenen LLM. The membrane of intact human erythrocyte tolerates only limited changes in the fatty acid composition of its phosphatidylcholine. Biochim Biophys Acta. 1984;769:337-347
49. Hagve TA, Lie O, Gronn M. The effect of dietary n-3 fatty acids on osmotic fragility and membrane fluidity of human erythrocytes. Scand J Clin Lab Invest. 1993;53(Suppl 215):75-84.
50. Hui DY, Noel JG, Harmony JAK. Binding of plasma low density lipoproteins to erythrocytes. Biochim Biophys Acta. 1981;664:513-526
51. Lange Y, Swaisgood MH, Ramos BV, Steck TL. Plasma membranes contain half the phospholipid and 90% of the cholesterol and sphingomyelin in cultured human fibroblasts. J Biol Chem. 1989;264:3786-3793
52. Ohvo-Rekila H, Ramstedt B, Leppimaki P, Slotte P. Cholesterol interactions with phospholipids in membranes. Prog Lipid Res. 2002;41:66-97.
53. Chen H, Born E, Mathur SN, Field FJ. Cholesterol and sphingomyelin syntheses are regulated independently in cultured human intestinal cells, CaCo-2: role of membrane cholesterol and sphingomyelin content. J Lipid Res. 1993;34:2159-2167
54. Chen H, Born E, Mathur SN, Johlin FC Jr, Field FJ. Sphingomyelin content of intestinal cell membranes regulates cholesterol absorption. Biochem J. 1992;286:771-777
55. Slotte JP, Bierman EL. Depletion of plasma -membrane sphingomyelin rapidly alters the distribution of cholesterol between plasma membranes and intracellular cholesterol pools in cultured fibroblasts. Biochem J. 1988;250:653-658